You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

October 9, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Dallas Ebola victim dies

Responding to requests from treating physicians, FDA has okayed brincidofovir for Emergency Investigational New Drug Applications, allowing it to be used in the treatment of the Ebola virus disease. » Read about this important development that may help combat this deadly virus

Study to measure impact of MTM on outcomes for IBD patients

The effectiveness of an inflammatory bowel disease (IBD) medication therapy management (MTM) patient fulfillment model and its impact on adherence compared to standard care will be evaluated in a new study.
» Read about this study with Johns Hopkins

Continuing Education

MTM essentials for anticoagulant management in cardiovascular disease

This month's article is the seventh in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the pharmacological properties, safety and efficacy, and risk/benefit profile for the various anticoagulant medications used in cardiovascular diseases.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT10-VXP89.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Humira approved for treating polyarticular juvenile idiopathic arthritis patients aged 2 and older

Humira was FDA approved for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 2 years and older. » Here's more on this most common form of childhood arthritis

 

Related Articles

WHO okays experimental drug use in Ebola outbreak

Medication therapy management program slashes medication expenses 200% with better outcomes

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group